Basel Medical Group Ltd key statistics and ratios

In fiscal 2026, Basel Medical Group Ltd had return on equity of -15.0%, a net margin of -4.5%, debt equal to 190.8% of equity and a current ratio of 1.23. Each ratio below is calculated from the figures on its income statement, balance sheet and cash flow pages.

Financial ratios

US$ thousands unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Basel Medical Group Ltd: financial ratios, annual
Fiscal year	2024Jun 2024	2025Jun 2025	2026Jun 2026
Net margin	20.6%	−94.0%	−4.5%
Free-cash-flow margin	24.9%	−40.6%	−5.4%
Return on equity	27.6%	−163.0%	−15.0%
Return on assets	12.8%	−60.1%	−4.1%
Asset turnover	0.62	0.64	0.90
Current ratio	2.26	1.31	1.23
Debt to equity	56.7%	93.4%	190.8%
Effective tax rate	13.8%	—	—
Capital spending as % of revenue	0.1%	4.9%	1.5%
Free cash flow ÷ net income	120.7%	—	—

Returns use average equity or assets over the year. Return on equity is left blank when equity is negative or so small that the ratio says nothing (above ±200%); interest cover is left blank above 200 times. Price-based ratios such as P/E are on the valuation page.

Financial health

2 of 5 checks passed · June 30, 2026

What it owns · $14m

Short-term assets $9mLonger-term assets $4m

What it owes, and who funded it · $14m

Short-term liabilities $8mLonger-term liabilities $3mShareholders' equity $4m

Short-term assets cover short-term liabilities $9m of assets due within a year against $8m of liabilities due within a year.
Short-term assets cover long-term liabilities $9m short-term assets against $3m of longer-dated liabilities.
More cash than debt $409,464 of cash against $7m of debt.
Debt below 40% of shareholders' equity Debt is 191% of equity.
Debt burden no higher than five years ago Five-year comparison not available. Not assessable.
A year's operating cash flow covers at least 20% of debt −$494,885 of operating cash flow against $7m of debt.
Operating profit covers interest at least five times over Interest not separately reported. Not assessable.

From Basel Medical Group Ltd's latest balance sheet as filed. Checks are fixed, documented rules (methodology), counted only where the company reports the figures — a dot means the filing doesn't break the item out. Descriptions of reported data, not advice.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Low.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Compare with peers

Head to head: BMGL vs NIVF BMGL vs CCM BMGL vs SNDA

More: Health Care Facilities stocks compared, Health Care sector, rankings of US companies

Figures from Basel Medical Group Ltd's SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Basel Medical Group Ltd.